Cure My Disease

Don't miss your cure!

 Log in / Sign up

Early trial tests experimental drug for Tough-to-Treat leukemias

NCT ID NCT05168202

Terminated Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This early-stage study aimed to find a safe dose and check for side effects of an experimental drug called CC-95251. It was tested alone and combined with other cancer drugs in 56 adults with advanced or returning forms of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The main goal was to see how well patients tolerated the treatment and to gather initial signs of whether it might help control their cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Local Institution - 0001

    Houston, Texas, 77030, United States

  • Local Institution - 0005

    Heidelberg, Victoria, 3084, Australia

  • Local Institution - 0006

    Clayton, Victoria, 3168, Australia

  • Local Institution - 0010

    Toronto, Ontario, M5G 2M9, Canada

  • Local Institution - 0011

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Local Institution - 0013

    Oslo, N-0027, Norway

  • Local Institution - 0014

    Stockholm, 141 86, Sweden

  • Local Institution - 0015

    Lund, 22185, Sweden

  • Local Institution - 0017

    Rozzano, 20089, Italy

  • Local Institution - 0018

    Meldola, Emilia-Romagna, 47014, Italy

  • Local Institution - 0019

    Edmonton, Alberta, T6G 2B7, Canada

  • Local Institution - 0020

    Pessac, 33600, France

  • Local Institution - 0021

    Gothenburg, 413 45, Sweden

  • Local Institution - 0023

    Toulouse, 31059, France

  • Local Institution - 0025

    Bergen, 5021, Norway

  • Local Institution - 0026

    Milan, 20162, Italy

  • Local Institution - 0027

    Wollongong, New South Wales, 2500, Australia

  • Local Institution - 0028

    Santander, 39008, Spain

  • Local Institution - 0029

    Nantes, 44000, France

  • Local Institution - 0030

    Los Angeles, California, 90095, United States

  • Local Institution - 0031

    Palo Alto, California, 94304, United States

  • Local Institution - 0032

    Badalona, Barcelona [Barcelona], 08916, Spain

  • Local Institution - 0035

    Salamanca, 37007, Spain

  • Local Institution - 0036

    Madrid, 28007, Spain

  • Local Institution - 0037

    Melbourne, Victoria, 3065, Australia

  • Local Institution - 0038

    Montreal, Quebec, H3T 1E2, Canada

  • Local Institution - 0039

    Barcelona, 08041, Spain

  • Local Institution - 0040

    Marseille, 13009, France

  • Local Institution - 0041

    Villejuif, 94805, France

  • Local Institution - 0044

    Edinburgh, Midlothian, EH4 2XU, United Kingdom

  • Local Institution - 0047

    Miami, Florida, 33136, United States

  • Local Institution - 0050

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

Conditions

Explore the condition pages connected to this study.

LEUKEMIA, MYELOID, ACUTE MYELODYSPLASTIC SYNDROMES